|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
19.010 +0.240 (+1.279%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Turnover | 286,042,998 | -2.946% | 294,726,810 | 300,950,280 | 261,471,723 | 249,120,231 |
| Cost of Sales | (265,696,092) | -2.598% | (272,783,515) | (277,679,599) | (239,814,229) | (228,533,008) |
| Gross Profit | 20,346,906 | -7.275% | 21,943,295 | 23,270,681 | 21,657,494 | 20,587,223 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | (987,599) | (710,546) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | 71,728 | -- | (175,995) | 128,201 | 38,093 | 75,259 | |
| Share of Results of Asso. & JCEs | 687,853 | 10.106% | 624,719 | 574,277 | 492,880 | 454,905 | |
| Profit / (Loss) before Taxation | 7,209,893 | -5.089% | 7,596,489 | 8,866,031 | 8,003,672 | 7,716,947 | |
| Taxation | (1,872,648) | 10.333% | (1,697,273) | (1,972,800) | (1,775,054) | (1,688,416) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,871,559) | -14.749% | (2,195,341) | (2,788,792) | (2,534,874) | (2,445,692) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,465,686 | -6.431% | 3,703,875 | 4,104,439 | 3,693,744 | 3,582,839 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 995,377 | -7.309% | 1,073,865 | 1,417,830 | 1,584,310 | 1,585,248 |
| Depreciation & Amortisation | 2,233,389 | -3.948% | 2,325,197 | 2,099,806 | 2,000,685 | 1,881,920 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| EPS (cts) | 111.000 | -6.723% | 119.000 | 132.000 | 118.000 | 115.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 25.710 | -- | 24.207 | 22.304 | 20.265 | 18.518 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,465,686 |
| %Change | -6.431% |
| EPS / (LPS) | RMB 1.110 |
| NBV Per Share (¥) | RMB 25.710 |